See more : Wus Printed Circuit (Kunshan) Co., Ltd. (002463.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Aion Therapeutic Inc. (ANTCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aion Therapeutic Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Zhejiang Tengen Electrics Co.,Ltd. (605066.SS) Income Statement Analysis – Financial Results
- Adcore Inc. (ADCOF) Income Statement Analysis – Financial Results
- Gram Car Carriers ASA (G39.BE) Income Statement Analysis – Financial Results
- Henan Hengxing Science & Technology Co.,Ltd. (002132.SZ) Income Statement Analysis – Financial Results
- PennyMac Mortgage Investment Trust (PMT-PB) Income Statement Analysis – Financial Results
Aion Therapeutic Inc. (ANTCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Aion Therapeutic Inc.
Aion Therapeutic Inc. offer medical cannabis products in Canada. The company was formerly known as Osoyoos Cannabis Inc. and changed its name to Aion Therapeutic Inc. in August 2020. Aion Therapeutic Inc. was incorporated in 2011 and is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 367.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 204.36K | 17.30K | 65.29K | 128.13K | 111.05K | 0.00 | 2.00K | 0.00 |
| Gross Profit | 163.12K | -17.30K | -65.29K | -128.13K | -111.05K | 0.00 | -2.00K | 0.00 |
| Gross Profit Ratio | 44.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 953.00K | 0.00 | 18.40K | 15.99K | 306.76K | 0.00 |
| General & Administrative | 967.81K | 738.50K | 1.13M | 2.17M | 579.12K | 1.02M | 127.50K | 51.27K |
| Selling & Marketing | 53.58K | 103.84K | 0.00 | 0.00 | 2.03K | 7.41K | 22.72K | 16.51K |
| SG&A | 1.02M | 842.33K | 1.13M | 2.17M | 579.12K | 1.03M | 150.22K | 67.78K |
| Other Expenses | -858.27K | 0.00 | 0.00 | 0.00 | 0.00 | -34.04K | 76.35K | 3.66K |
| Operating Expenses | 163.12K | 842.33K | 2.82M | 2.78M | 982.64K | 1.70M | 207.43K | 125.58K |
| Cost & Expenses | 367.48K | 842.33K | 2.82M | 2.78M | 982.64K | 1.70M | 207.43K | 125.58K |
| Interest Income | 14.99K | 149.84 | 75.72 | 186.07 | 321.19 | 679.12 | 0.00 | 0.00 |
| Interest Expense | 171.39K | 149.84K | 75.72K | 186.07K | 321.19K | 679.12K | 9.04K | 11.37K |
| Depreciation & Amortization | 42.11K | 17.30K | 65.29K | 128.13K | 111.05K | 1.49M | 2.53M | 52.52K |
| EBITDA | -6.07M | -842.33K | -2.33M | -2.47M | -851.62K | 0.00 | 0.00 | -121.92K |
| EBITDA Ratio | -1,652.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 0.00 | -842.33K | -2.82M | -2.78M | -996.64K | -1.70M | -131.08K | -121.92K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.29M | 585.68K | -1.49M | -5.79M | 178.79K | -3.44M | -314.21K | -1.38M |
| Income Before Tax | -6.29M | -256.66K | -3.82M | -8.27M | -672.83K | -4.93M | -140.11K | -1.51M |
| Income Before Tax Ratio | -1,710.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 41.03K | 75.72K | 186.07K | 321.19K | 677.63K | -2.44M | -37.49K |
| Net Income | -6.29M | -256.66K | -3.82M | -8.27M | -672.83K | -4.93M | -140.11K | -1.51M |
| Net Income Ratio | -1,710.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | -0.03 | -0.09 | -0.02 | -0.18 | 0.00 | -0.04 |
| EPS Diluted | 0.00 | 0.00 | -0.03 | -0.09 | -0.02 | -0.18 | 0.00 | -0.04 |
| Weighted Avg Shares Out | 0.00 | 146.40M | 139.89M | 93.90M | 35.89M | 27.48M | 34.67M | 34.67M |
| Weighted Avg Shares Out (Dil) | 0.00 | 146.40M | 139.89M | 93.90M | 35.89M | 27.48M | 34.67M | 34.67M |
Aion Therapeutic Announces Revocation of MCTO
Toronto, Ontario--(Newsfile Corp. - November 13, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it has received an order from the British Columbia Securities Commission (the "BCSC") revoking the management cease...
Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Toronto, Ontario--(Newsfile Corp. - October 24, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by...
Aion Therapeutic Hires CRO for Toppen Health; Announces Director Resignation
Toronto, Ontario--(Newsfile Corp. - October 23, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company"), through its water filtration subsidiary, Toppen Health, Inc. ("Toppen" or "Toppen Health"), is excited to announce the appointment of Charles Freihofer as...
Aion Therapeutic Announces Non- Brokered Private Placement Offering of Units
Toronto, Ontario--(Newsfile Corp. - October 21, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement offering (the "Offering") of up to 33,333,333 units ("Units"),...
Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by...
Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Toronto, Ontario--(Newsfile Corp. - September 26, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by...
Aion Therapeutic Announces Closing of First Tranche of Non-Brokered Private Placement Offering of Units
Toronto, Ontario--(Newsfile Corp. - September 20, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its non-brokered private placement offering (the "Offering")...
Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Toronto, Ontario--(Newsfile Corp. - September 12, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by...
Aion Therapeutic Announces Grant of Management Cease Trade Order
Toronto, Ontario--(Newsfile Corp. - August 29, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that further to its release issued on August 14, 2024 in respect of its application to the British Columbia Securities...
Aion Therapeutic Announces Non-Brokered Private Placement Offering of Units
Toronto, Ontario--(Newsfile Corp. - August 23, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement offering (the "Offering") of up to 45,454,545 units ("Units"),...
Source: https://incomestatements.info
Category: Stock Reports